[1]Thrift AP, El-Serag HB. Burden of gastric cancer[J]. Clin Gastroenterol Hepatol, 2020, 18: 534-542. [2]Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer[J]. Tumour Biol, 2017, 39: 1010428317714626. doi: 10.1177/1010428317714626. [3]Huang S, Wa Q, Pan J, et al. Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer[J]. J Exp Clin Cancer Res, 2017, 36: 173. doi: 10.1186/s13046-017-0645-7. [4]Liang Z, Li X, Liu S, et al. miR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer[J]. Biochem Biophys Res Commun, 2019, 514: 699-705. [5]Yang X, Wang P. miR-188-5p and miR-141-3p influence prognosis of bladder cancer and promote bladder cancer synergistically[J]. Pathol Res Pract, 2019, 215: 152598. doi: 10.1016/j.prp.2019.152598. [6]Lei K, Liang X, Gao Y, et al. Lnc-ATB contributes to gastric cancer growth through a miR-141-3p/TGFβ2 feedback loop[J]. Biochem Biophys Res Commun, 2017, 484: 514-521. [7]Shin VY, Chu KM. miRNA as potential biomarkers and therapeutic targets for gastric cancer[J]. World J Gastroenterol, 2014, 20: 10432-10439. [8]Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancer early diagnosis[J]. World J Gastroenterol, 2019, 25: 2029-2044. [9] Mishra A, Verma M. Epigenetic and genetic regulation of PDCD1 gene in cancer immunology[J]. Methods Mol Biol, 2018, 1856: 247-254. [10]Qin Y, Vasilatos SN, Chen L, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade[J]. Oncogene, 2019, 38: 390-405. [11]Wang S, Li J, Xie J, et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway[J]. Oncogene, 2018, 37: 4164-4180. [12]Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer[J]. Ann Oncol, 2016, 27: 409-416. [13]Noman MZ, Janji B, Abdou A, et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200[J]. Oncoimmunology, 2017, 6: e1263412. doi: 10.1080/2162402X.2016.1263412. eCollection 2017. [14]Wang B, Qin L, Ren M, et al. Effects of combination of anti-CTLA-4 and anti-PD-1 on gastric cancer cells proliferation, apoptosis and metastasis[J]. Cell Physiol Biochem, 2018, 49: 260-270. |